Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition
摘要:
Dimeric norspermidine and spermidine derivatives are strong competitive inhibitors of polyamine transport. A xylyl tether was used for the dimerization of various triamines and spermine via a secondary amino group, and of putrescine via an ether or an amino group. Dimerization of putrescine moieties potentiates their ability to compete against spermidine transport to a much greater extent than for triamine dimers. (C) 2003 Elsevier Ltd. All rights reserved.
[EN] ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY<br/>[FR] BISAMINOQUINOLINES ASYMÉTRIQUES ET BISAMINOQUINOLINES COMPORTANT DIVERSES SÉQUENCES DE LIAISON POUVANT ÊTRE UTILISÉES EN TANT QU'INHIBITEURS DE L'AUTOPHAGIE POUR LE TRAITEMENT DU CANCER ET D'AUTRES MALADIES
申请人:UNIV PENNSYLVANIA
公开号:WO2016022956A1
公开(公告)日:2016-02-11
The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor
作者:Yanan Zhang、Anne Gilliam、Rangan Maitra、M. Imad Damaj、Julianne M. Tajuba、Herbert H. Seltzman、Brian F. Thomas
DOI:10.1021/jm1006676
日期:2010.10.14
(GPCRs), including the cannabinoid 1 (CB1) receptor, is now widely accepted and may have significant implications for medications development targeting these receptor complexes. A library of bivalentligands composed of two identical CB1 antagonist pharmacophores derived from SR141716 linked by spacers of various lengths were developed. The affinities of these bivalentligands at CB1 and CB2 receptors
Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
申请人:THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
公开号:US10221140B2
公开(公告)日:2019-03-05
The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.